Menopause and Age-Related Concerns

Journal of Obstetrics and Gynaecology Canada

Volumn 28, Issue 2, 2006, Pages S21-S32

  Desindes, Sophie ^a   Bélisle, Serge ^a   Graves, Gillian ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; BELLERGAL; CLONIDINE; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; GLUCOSAMINE; HYPNOTIC AGENT; ISOFLAVONE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHYTOESTROGEN; PROGESTERONE; VALERIAN; VENLAFAXINE;

ABNORMAL UTERINE BLEEDING; ACTAEA RACEMOSA; ACUPUNCTURE; AGE RELATED MACULAR DEGENERATION; AGING; ARTHRALGIA; ARTICLE; BEHAVIOR THERAPY; BONE DENSITY; CATARACT; CORE TEMPERATURE; DISEASE ASSOCIATION; EXERCISE; EYE DISEASE; FEMALE; GINGIVA BLEEDING; GINGIVITIS; HORMONAL THERAPY; HUMAN; HYPERICUM PERFORATUM; INSOMNIA; LIFESTYLE MODIFICATION; MENOPAUSE; MOUTH HYGIENE; MULTICENTER STUDY (TOPIC); PERIODONTAL DISEASE; POSTMENOPAUSE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED CLOVER; SKIN DISEASE; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SMOKING CESSATION; SOYBEAN; THERMOREGULATION; UTERUS BLEEDING; VASOMOTOR DISORDER; WEIGHT GAIN;

EID: 34547814098     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32078-3     Document Type: Article

References (97)

1. Shanafelt T.D., Barton L.B., Adjei A.A., Loprinzi C.L. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002, 77:1207-1218.
2. KRodstrom Rodstrom, KRodstrom KRodstrom K., Bengtsson C., Lissner L., Milsom I., Sundh V., Bjorkelund C. A longitudinal study of the treatment of hot flushes. Menopause 2002, 9:156-161.
3. Avis N.E., Crawford S.L., McKinlay S.M. Psychological, behavioural, and health factors related to menopause symptomatology. Womens Health 1997, 3:103-120.
4. Gold E.B., Sternfeld B., Kelsey J.L., Brown C., Mouton C., Reame N., et al. Relation of demographic and lifestyle factors to symptoms in a multiracial ethnic population of women 40-55 years of age. Am J Epidemiol 2000, 152:463-473.
5. Randolph J.F., Sowers M., Gold E.B., Mohr B.A., Luborsky J., Santoro N., et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003, 88:1516-1522.
6. Guthrie J.R., Dennerstein L., Hopper J.L., Burger H.G. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol 1996, 88:437-442.
7. Chakravarti S., Collins W.P., Newton J.R., Oram D.H., Studd J.W. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol 1977, 84:769-775.
8. Freedman R.R. Hot flash etiology: new directions for research. Menopause Management 2002, 11(4):8-14.
9. MacLennan A., Lester S., Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review). Cochrane Database Syst Rev 2001, 1. CD002978.
10. Kronenberg F., Barnard R.M. Modulation of menopausal hot flashes by ambient temperature. J Therm Biol 1992, 17:43-49.
11. Freedman R.R., Woodward S., Brown B., Javaid J.L., Pandey G.N. Biochemical and thermoregulatory effects of behavioural treatment for menopausal hot flashes. Menopause 1995, 2:211-218.
12. Irvin J.H., Domar A.D., Clarck C., Zuttermeister P.C., Friedman R. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol 1996, 17:202-207.
13. McFarland B., Bigelow D., Zani B., Newsom J., Kaplan M. Complementary and alternative medicine use in Canada and the United States. Am J Public Health 2002, 92(10):1616-1618.
14. Huntley A.L., Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003, 10:465-476.
15. Kronenberg F., Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002, 137:805-813.
16. Levitsky J., Alli T.A., Wisecarver J., Sorrell M.F. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2005, 50(3):538-539.
17. van de Weijer P.H.M., Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002, 42(3):187-593.
18. Krebs E.E., Ensrud K.E., MacDonald R., Wilt T.J. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004, 104:824-836.
19. Barton D.L., Loprinzi C.L., Quella S.K., Sloan J.A., Veeder M.H., Egner J.R., et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998, 16(2):495-500.
20. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., et al. The HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. J Am Med Assoc 2005, 293:1338-1347.
21. Barnabei V.M., Cochrane B.B., Aragaki A.K., Nygaard I., Williams R.S., McGovern P.G., et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005, 105(5):1063-1073.
22. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004, 7(4):347-356.
23. Utian W.H., Shoupe D., Bachmann G., Pinkerton J.V., Pickar J.H. Relief of vasomotor symptoms and vaginal atrophy with low doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001, 75:1065-1079.
24. Crandall C. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J Womens Health 2003, 12:723-747.
25. Raudaskoski T.H., Lahti E.I., Kauppila A.J., Apaja-Sarkkinen M.A., Laatikainen T.J. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995, 172:114-119.
26. Suvanto-Luukkonen E., Malinen H., Sundstrom H., Penttinen J., Kauppila A. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998, 77(7):758-763.
27. Wildemeersch D., Schacht E. Endometrial suppression with a new-frameless-levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study. Maturitas 2000, 361:63-68.
28. Sanada M., Tsuda M., Kodama I., Sakashita T., Nakagawa H., Ohama K. Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia. Menopause 2004, 11(3):331-336.
29. Kraemer G.R., Kraemer R.R., Ogden B.W., Kilpatrick R.E., Gimpel T.L., Castracane V.D. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril 2003, 79(3):534-542.
30. Basbug M., Aygen E., Tayyar M., Muhtaroglu S., Demir I., Okten S. Twenty-two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women. Eur J Obstet Gynecol Reprod Biol 1997, 73(2):149-152.
31. Schiff I., Tulchinski D., Cramer D., Ryan K.J. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. J Am Med Assoc 1980, 244(13):1443-1445.
32. Bullock J.L., Massey F.M., Gambrell R.D. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975, 46:165-168.
33. Loprinzi C.L., Michalak J.C., Quella S.K., O'Fallon J.R., Hatfield A.K., Nelimark R.A., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994, 331:347-352.
34. Casper R.F., Dodin S., Reid R.L. Study Investigators The effect of 20 micrograms ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997, 4:139-147.
35. Shargil A.A. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil 1985, 30:15-28.
36. Kaunitz A.M. Oral contraceptive use in perimenopause. Am J Obstet Gynecol 2001, 185:S32-S37.
37. Black A., Francoeur D., Rowe T., Collins J., Miller D., Brown T., et al. SOGC clinical practice guidelines: Canadian contraception consensus. J Obstet Gynaecol Can 2004, 26(3):219-296.
38. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., LaVasseur B.I., Barton D.L., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000, 356:2059-2063.
39. Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002, 20:1578-1583.
40. Stearns V., Beebe K.L., Iyengar M., Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. J Am Med Assoc 2003, 289(21):2827-2834.
41. Stearns V., Isaacs C., Rowland J., Crawford J., Ellis M.J., Kramer R., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000, 11(1):17-22.
42. Suvanto-Luukkonen E., Koivunen R., Sundstrom H., Bloigu R., Karjalainen E., Haiva-Mallinen L., et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005, 12(1):18-26.
43. Guttuso T., Kurlan R., McDermott M.P., Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003, 101(2):337-345.
44. Pandya K.J., Raubertas R.F., Flynn P.J., Hynes H.E., Rosenbluth R.J., Kirshner J.J., et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000, 132(10):788-793.
45. Kravitz H.M., Ganz P.A., Bromberger J., Powell L.H., Sutton-Tyrrell K., Meyer P.M. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003, 10(1):19-28.
46. Eichling P.S. Evaluating and treating menopausal sleep problems. Menopause Management 2002, 11(5):8-17.
47. Lustberg L., Reynolds C.F. Depression and insomnia: questions of cause of effect. Sleep Med Rev 2000, 4:253-262.
48. Dancey D.R., Hanly P.J., Soong C., Lee B., Hoffstein V. Impact of menopause on the prevalence and severity of sleep apnea. Chest 2001, 120:151-155.
49. Keefe D.L., Watson R., Naftolin F. Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. Menopause 1999, 6:196-200.
50. Polo-Kantola P., Rauhala E., Helenius H., Erkkola R., Irjala K., Polo O. Breathing during sleep in menopause: a randomized, controlled, crossover trial with estrogen therapy. Obstet Gynecol 2003, 102(1):68-75.
51. Montplaisir J., Lorrain J., Denesle R., Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001, 8(1):10-16.
52. Wing R.R., Matthews K.A., Kuller L.H., Meilahn E.N., Plantinga P.L. Weight gain at the time of menopause. Arch Int Med 1991, 151:97-102.
53. Poehlman E.T., Goran M.I., Gardner A.W., Ades P.A., Arciero P.J., Katzmann-Rooks S.M. Determinants of decline in resting metabolic rate in ageing females. Am J Physiol 1993, 264-273. Pt 1):E450-E455.
54. Norman R.J., Flight I.H., Rees M.C. Estrogen and progestin hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev 2000, 2.
55. Espeland M.A., Stefanick M.L., Kritz-Silverstein D., Fineberg S.E., Waclawiw M.A., James M.K., et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen/Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997, 82:1549-1556.
56. van Seumeren I. Weight gain and hormone replacement therapy: are women's fears justified?. Maturitas 2000, 34(Suppl 1):S3-S8.
57. Sternfeld B., Wang H., Quesenberry C.P., Abrams B., Everson-Rose S.A., Greendale G.A., et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol 2004, 160(9):912-922.
58. Simkin-Silverman L.R., Wing R.R., Boraz M.A., Kuller L.H. Lifestyle intervention can prevent weight gain during menopause: results from a 5-year randomised clinical trial. Ann Behav Med 2003, 26(3):212-220.
59. Obermeyer C.M., Reynolds R.F., Price K., Abraham A. Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts. Menopause 2004, 11(4):456-465.
60. Zhang Y., McAlindon T.E., Hannan M.T., Chaisson C.E., Klein R., Wilson P.W., et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham study. Arthritis Rheum 1998, 41:1867-1873.
61. ACOG Task Force on Hormone Therapy Osteoarthritis. Obstet Gynecol 2004, 104(suppl):62S-65S.
62. Towheed T., Maxwell L., Anastassiades T., Shea B., Houpt J., Robinson V. 62. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, (2):CD002946. Apr 18.
63. Brincat M., Moniz C.F., Studd J.W.W., Darby A.J., Magos A.L., Cooper D.J. Sex hormones and skin collagen in post-menopausal women. BMJ 1983, 287:1337-1338.
64. Pierard G.E., Letawe C., Dowlati A., Pierard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995, 43:662-665.
65. Punnonen R., Vaajalahti P., Tiesala K. Local oestradiol treatment improves the structure of elastic fibres in the skin of postmenopausal women. Ann Chir Gynaecol Suppl 1987, 76:39-41.
66. Maheux R., Naud F., Rioux M. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994, 170:642-649.
67. Creidi P., Faivre B., Agache P., Richard E., Haudiquet V., Sauvanet J.P. Effect of a conjugated oestrogen (Premarin) cream on aging facial skin: a comparative study with a placebo cream. Maturitas 1994, 19:211-223.
68. Henry F., Pierard-Franchimont C., Cauwenbergh G., Pierard G.E. Age related changes in facial skin contours and rheology. J Am Geriatr Soc 1997, 45:220-222.
69. Atra R.S., Dover J.S., Hobbs L., Phillips T.J. Evaluation of the role of exogenous estrogen in postoperative progress after laser skin resurfacing. Dermatol Surg 2003, 29:43-48.
70. Colton T., Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol 1980, 25:123-129.
71. Mathers W.D., Lane J.A., Zimmerman M.B. Tear film changes associated with normal aging. Cornea 1996, 15:229-234.
72. Hennelly M.L., Barbur J.L., Edgar D.F., Woodward E.G. The effect of age on the light scattering characteristics of the eye. Ophthalmic Physiol Opt 1998, 18:197-203.
73. Dolatowska E. The evaluation of estradiol and FSH serum levels in menopausal women with primary cataract. Klin Oczna 2002, 104:357-361.
74. Lee S.M., Tseng L.M., Li A.F., Liu H.C., Liu T.Y., Chi C.W. Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses 2004, 63:494-497.
75. Younan C., Mitchell P., Cumming R.G., Panchapakesan J., Rochtchina E., Hales A.M. Hormone replacement therapy, reproductive factors and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 2002, 155:997-1006.
76. Benitez del Castillo J.M., del Rio T., Garcia-Sanchez J. Effects of estrogen use on transmittance in postmenopausal women. Ophthalmology 1997, 104:970-973.
77. Freeman E.E., Munoz B., Schein O.D., West S.K. Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors. Epidemiology 2004, 4:451-457.
78. Guashino S., Grimaldi E., Sartore A., Mugittu R., Mangino F., Bortoli P., et al. Visual function in menopause: the role of hormone replacement therapy. Menopause 2003, 10(1):53-57.
79. Altintas O., Caglar Y., Yuksel N., Demirci A., Karabas L. The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica 2004, 218(2):120-129.
80. Smith W., Mitchell P., Wang J.J. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust NZ J Ophthalmol 1997, 25(9):S13-S15. Suppl 1.
81. Snow K.K., Cote J., Yang W., Davis N.J., Seddon J.M. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. Am J Ophthalmol 2002, 134:842-848.
82. Defay R., Pinchinat S., Lumbroso S., Sutan C., Delcourt C., Pola Study Group Sex steroids and age-related macular degeneration in older French women: the POLA study. Ann Epidemiol 2004, 14:202-208.
83. von Wowern N. General and oral aspects of osteoporosis: a review. Clin Oral Investig 2001, 5(2):71-82.
84. Laine M.A., Sewon L.A., Karjalainene S.M., Helenius H., Doroguinskaia A., Lehtonene-Veromaa M. Salivary variables in relation to tobacco smoking and female sex steroid hormone-use in 30- to 59-year-old women. Acta Odontol Scand 2002, 60(4):237-240. Erratum in 60(6):375.
85. Civitelli R., Pildram T.K., Dotson M., Muckerman J., Lewandowski N., Armamento-Villareal R., et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized double-blind, placebo-controlled trial. Arch Intern Med 2002, 162(12):1409-1415.
86. Lopez-Marcos J.F. Garcia-Valle, Garcia-Iglesias AA. Periodontal aspects in menopausal women undergoing hormone replacement therapy. Med Oral Patol Cir Bucal 2005, 10(2):132-141.
87. Paginini-Hill A. Estrogen replacement therapy-something to smile about. Compend Contin Educ Dent Suppl 1998, 22:S4-S8.
88. Speroff L. Unpublicized effects of postmenopausal hormone therapy. Ob/Gyn Clinic Alert 1996, 6-8. May.
89. Hakeberg M., Berggren U., Hagglin C., Ahlqwist M. Reported burning mouth symptoms among middle-aged and elderly women. Eur J Oral Sci 1997, 105:539-543.
90. Burger H.G., Robertson D.M., Baksheev L., Collins A., Csemiczky G., Landgren B.M. The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause 2005, 12(3):267-274.
91. SOGC Guidelines Guidelines for the management of abnormal uterine bleeding. SOGC Clinical Practice Guideline No. 106. J Soc Obstet Gynaecol Can 2001, 23(12).
92. Grady D., Ettinger B., Tosteson A.N.A., Pressman A., Macer J.L. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003, 102:1233-1239.
93. Clarke S.C., Kelleher J., Lloyd-Jones H., Slack M., Schofield P.M. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002, 109:1056-1062.
94. Ettinger B., Ensrud K.E., Wallace R., Johnson K.C., Cummings S.R., Yankov V., et al. Effects of ultra-low-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004, 104(3):443-451.
95. Johnson S.R., Ettinger B., Macer J.L., Ensrud K.E., Quan J., Grady D. Uterine and vaginal effects of unopposed ultra-low-dose transdermal estradiol administered to postmenopausal women for 2 years. Obstet Gynecol 2005, 105:779-787.
96. Cushing K.L., Weiss N.S., Voigt L.F., McKnight B., Beresford S.A. Risk of endometrial cancer in relation to use of low dose unopposed estrogens. Obstet Gynecol 1998, 91:35-39.
97. Lethaby A., Suckling J., Barlow D., Farquhar C.M., Jepson R.G., Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000, 2. CD000402.